ZOLL Medical Corporation (NasdaqGS: ZOLL), a manufacturer of resuscitation devices and software solutions, announced that fiscal 2009 revenues were $385.2 million, compared to fiscal 2008 revenues of $398.0 million, a decline of 3%. Revenue results reflected a negative foreign exchange impact of nearly $12 million compared to fiscal 2008. The results include approximately $6.9 million of revenue derived from our new Temperature Management business, whose assets were acquired from Alsius Corporation in May 2009. Net income for the year was $9.6 million, compared to $23.4 million in the prior year. Diluted earnings per share were $0.45, compared to $1.10 in the prior year. Backlog at the end of the year was approximately $19.7 million, as compared to $7.9 million at the end of the prior fiscal year and $9.8 million at the end of Q3 2009.
Annual sales to the North American market decreased 5% to $287.6 million, compared to $301.4 million for the prior year. Sales to the North American hospital market decreased 20% to $93.3 million, compared to $117.1 million last year. Excluding U.S. Military sales, North American hospital sales decreased 25% from $90.9 million to $68.6 million. U.S. Military sales were $24.7 million, compared to $26.2 million in the prior year period. Sales to the North American pre-hospital market increased 6% to $171.2 million, compared to $161.7 million in the prior year. International revenues increased by 1% to $97.6 million, compared to $96.6 million last year. LifeVest revenues increased 66% to $43.9 million compared to $26.5 million last year. Total AutoPulse sales decreased 6% to $16.7 million for the year, compared to $17.8 million in the prior year.
Fourth-quarter revenues for fiscal year 2009 increased 2% to $107.9 million, compared to $105.6 million in the fourth quarter of last year. Revenue results reflected a negative foreign exchange impact of approximately $1.4 million compared to the fourth quarter of fiscal 2008. The fourth quarter results include approximately $5 million of revenue derived from our newly acquired Temperature Management business. Net income decreased 62% to $3.4 million, compared to $8.9 million in the prior-year period, and diluted earnings per share decreased 61% to $0.16 per share, compared to $0.41 in the fourth quarter of last year.
Fourth-quarter sales to the North American market decreased 2% to $79.1 million, compared to $81.1 million in the fourth quarter of 2008. Sales to the North American hospital market decreased 3% to $28.9 million, compared to $29.7 million in the fourth quarter of last year. Excluding the U.S. Military, sales to the North American hospital market decreased 16% to $20.0 million, compared to $23.8 million in the prior-year quarter. Sales to the U.S. Military increased to $8.9 million, compared to $5.9 million in the prior year. Sales to the North American pre-hospital market decreased 2% to $44.5 million, compared to $45.6 million for the same period last year. International sales increased by 17% to $28.8 million, compared to $24.5 million in the fourth quarter last year. Total LifeVest revenues increased 59% to $12.9 million as compared to $8.1 million in the prior-year quarter. Total AutoPulse shipments to all markets decreased by 41% to $4.1 million, compared to $7.0 million in the fourth quarter of the prior year.
Gross margin for the fourth quarter was 50%, compared to 55% in the fourth quarter of fiscal 2008. The decrease was attributable to many factors including, but not limited to, reduced factory absorption due to the impact of lower production volumes of core defibrillators, foreign exchange and the mix of foreign sales, the inclusion of the newly acquired Temperature Management business which is in the early stages of ramp up, and higher than normal North American sales incentives and promotions necessary to motivate capital equipment purchases in a climate of economic uncertainty. These factors were partially offset by the favorable impact resulting from an increased mix of sales from the LifeVest product.
No Comment Received
Leave A Reply